Zydus Lifesciences Ltd (ZYDUSLIFE) — Announcement | 28 September 2026
Zydus Lifesciences announced that the USFDA closed its cGMP inspection of the Ahmedabad SEZ II plant on September 28, 2026, with one observation and no data integrity issues, marking a positive regulatory outcome for its manufacturing operations.
About Zydus Lifesciences Ltd (ZYDUSLIFE)
Healthcare · Pharmaceuticals · Listed on BSE
📡 Get AI alerts when ZYDUSLIFE files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track ZYDUSLIFE — Free💡 Ask AI about this filing
📊 More ZYDUSLIFE filings
- 🔴 Announcement — 26 September 2026Zydus Lifesciences announced that the USFDA completed an inspection of its New Jersey pharmacovigila...
- Announcement — 26 September 2026Zydus Lifesciences has announced a trading window closure effective October 1, 2026, through October...
- 🔴 Announcement — 11 September 2026Zydus Lifesciences announced that CRISIL reaffirmed its long-term rating of CRISIL AAA/Stable and sh...
- 🔴 Announcement — 11 September 2026Zydus Lifesciences announced it will attend the J.P. Morgan India Conference on September 21, 2026, ...
- Announcement — 5 September 2026Zydus Lifesciences disclosed that its U.S. subsidiary ZPUI settled indirect reseller claims in the G...
🔥 Also filed on 28 September 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when ZYDUSLIFE files new disclosures
Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ZYDUSLIFE — FreeFree account · 2 AI queries/day